

Date: 18th January, 2016

To
The Manager
Department of Corporate Services
Bombay Stock Exchange Ltd.
Dalal Street, Fort
Mumbai - 400 001

Sub. - : Disclosure of Event under Regulation 30

Ref. -: Scrip Code - 524764

Sir / Madam,

With regards to the captioned subject we would like to inform you that the Company has commenced commercial production in its new plant at Tarapur for anti-malarial drug LUMEFANTRINE.

Previously company was engaged in the manufacturing of Intermediate of the same drug (i.e. n-2 stage) at its existing factory and was selling to the various pharma companies.

Now Company is manufacturing the final end product (i.e. LUMEFANTRINE) on full fledge basis at Company's New Production Facilities. The Company has obtained necessary approvals and has commenced the commercial production of LUMEFANTRINE. This is a forward integration and shall result in better margin.


The Company expects to achieving full production capacities in next 3 month in its plant.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

Yours faithfully,

For **Nutraplus India Limited**



Uday Mukesh Desai

Director

DIN: 00413093

